French Randomized Sentinel Node Multicentric Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 14
研究概览
简要总结
RATIONALE: It is not yet known whether injecting technetium Tc 99m sulfur colloid and blue dye near the tumor is more effective than injecting them near the nipple in identifying sentinel lymph nodes in patients with stage I or stage II breast cancer.
PURPOSE: Randomized diagnostic trial to compare the effectiveness of injecting technetium Tc 99m sulfur colloid and blue dye near the tumor with that of injections around the nipple in detecting sentinel lymph nodes in patients who have stage I or stage II breast cancer.
详细描述
OBJECTIVES:
- Determine the optimal mode of injection (peritumoral vs periareolar) of patent blue V dye and technetium Tc 99m sulfur colloid in patients with stage I or II breast cancer undergoing sentinel lymph node identification.
- Determine the reduction of morbidity associated with breast cancer surgery, in terms of local control and survival, in patients undergoing sentinel lymph node identification with these drugs.
- Determine the evolution of disease in patients who have undergone this procedure and do not show histological invasion of the sentinel lymph node.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive peritumoral injections of patent blue V dye and technetium Tc 99m sulfur colloid.
- Arm II: Patients receive periareolar injections as in arm I. Patients in both arms showing histological metastasis of the sentinel lymph node or without identification of the sentinel lymph node undergo standard axillary lymph node dissection.
Patients are followed for disease evolution.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Diagnostic
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed invasive breast cancer
- •T0, T1, or T2 no greater than 3 cm, N0
- •Amenable to surgery
- •No inflammatory breast cancer
- •No ductal cancer in situ or multicentric invasive ductal cancer
- •No nipple/areola or central breast cancer (at least 2 cm from areola)
- •No metastatic disease
- •Hormone receptor status:
- •Not specified
- •PATIENT CHARACTERISTICS:
- •Not specified
- •Menopausal status
- •Not specified
- •Performance status
- •Not specified
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Not specified
- •Not specified
- •Not specified
- •Not pregnant
- •Negative pregnancy test
- •No known allergy or intolerance to patent blue V dye
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •Not specified
- •Chemotherapy
- •Not specified
- •Endocrine therapy
- •Not specified
- •Radiotherapy
- •Not specified
- •No prior surgery for cancer
- •No prior neoadjuvant treatment for cancer
排除标准
- 未提供
